Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
It is not available on the NHS, holds no UK Summary of Product Characteristics, and any retatrutide outside formal clinical trials is classified as a research chemical
BPC-157 remains investigational with limited human clinical data
AMPK Activation
Mechanism of Action Stimulates angiogenesis (formation of new blood vessels) Increases fibroblast activity and collagen synthesis Reduces pro-inflammatory cytokines and promotes anti-inflammatory cascades Enhances tendon-to-bone healing , muscle fiber regeneration, and gut lining repair Works through interaction with the nitric oxide system , aiding circulation and tissue oxygenation BPC157 promotes tendon and ligament healing, accelerates wound closure, and stabilizes vascular response after injury. Sikiric et al., Current Pharmaceutical Design Applications Joint pain, tendonitis, ligament tears Ulcers, IBS, leaky gut Muscle strain, post-surgical recovery Neural repair and recovery from nerve compression Post-cycle inflammation and tissue stress Delivery Administered via subcutaneous injection , near site of injury or systemically Can also be taken orally for GI-related issues (due to gastric stability) BPC157 Overview and How It Works BPC157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice
Mark each vial clearly with the date of first puncture and the 28-day discard date using permanent marker
The injectable NAD+ 500mg vial is intended for parenteral research models (subcutaneous or intravenous administration), achieving high plasma and tissue NAD+ levels directly
US$ 27.89
US$ 29.39
US$ 21.37
US$ 23.23
US$ 28.28
US$ 26.71
US$ 23.25